Biosimilars: the challenges and how to overcome them
Chaired by Dr Paul Cornes, this IME webcast discusses the common barriers to the effective uptake of biosimilars in oncology clinical practice, and what different multidisciplinary team members can learn from each other to overcome these challenges.
Don't have an account?
|Welcome and introduction
|The pharmacist’s perspective||Mathias Flume|
|The rheumatologist’s perspective||Tore Kvien|
|The oncologist’s perspective||Paul Cornes|
|How can we improve biosimilar uptake as a multidisciplinary team?||All
(Panel discussion moderated by Paul Cornes)
|Summary and close||Paul Cornes|
All medical oncologists, specialist nurses and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.
After participating in this webcast you will be able to
- Discuss the benefits of biosimilars in the oncology setting and build confidence amongst multidisciplinary colleagues
- Debate the challenges facing biosimilar uptake and potential strategies to overcome these
Faculty and disclosures
Dr Paul Cornes (BM BCH MA MRCP FRCR) has trained in Medicine at Oxford University and in Oncology at the Royal Marsden Hospital, London, UK before becoming a Consultant Oncologist in Bristol, UK.
He is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment. He was on the faculty for the annual ECCO European CanCer Organisation meeting and ESMO-Barcelona – speaking on Innovation and Value-based medicine.
Paul was part of the team that developed and presented evidence to the Oncologic Drugs Advisory Committee of the FDA for the first successfully approved US biosimilar. He is a faculty member for the Continuing Medical Education programme of the European Association of Hospital Pharmacists for 2016, 2017 & 2018 and a Core Lecturer for the European School of Oncology.
He is part of the British Medical Journal “Round Table” group on Biosimilars as well as a faculty member for the DIA Regulators Meeting on Biosimilars. He has been an adviser on medicines and biosimilars policy to several national health systems – both in the EU and beyond.
Paul Cornes has received travel costs to attend meetings and/or received speaker fees from Accord Healthcare; Astro; Biogen; the European Commission; the Global Academy of Health Sciences; GBM-Australia; Mylan, Napp; Pfizer/Hospira; Sandoz.
Dr Mathias Flume is Head of Business Unit Prescription Management at the National Association of Statutory Health Insurance Physicians in Westfalia-Lippe, Germany. He is in charge of the management and development of the Business Unit responsible for all prescriptions of approximately 11,000 doctors, contracting with sick funds etc. and his professional interest focuses on the assessment of innovative drugs and their implementation in regional prescription management.
Dr Flume has also worked as a consultant focusing on German and European HTA topics. He has extensive experience with AMNOG process, dossier reviews and support in the development of clinical trial designs from a HTA perspective.
He studied Pharmacy at the University of Muenster and obtained a PhD in 2001. In 2008 he obtained an executive MBA at the Kellogg School of Management, Chicago, USA and WHU-Otto Beisheim School of Management in Vallendar, Germany.
Dr. Flume received honoraria (Iqvia, CBP) for participation in the following activities between 2016-2019, related to biosimilars:
- Market research interviews
- One day advisory boards around biosimilars
- No continuous relationship to any manufacturer of biologics
Tore K. Kvien has served as Professor of Rheumatology at the University of Oslo, Norway, since 1997 and was Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo, Norway from 1994 until 2019. His current primary research activities include clinical and epidemiological research, with an emphasis on joint diseases.
Professor Kvien initiated a collaborative project in Norway on very early arthritis and is the leader of the Norwegian NOR-DMARD registry, an observational study of prescriptions of DMARDs and biological agents in Norway. He has published more than 550 research articles in international peer-reviewed journals, was the Editor-in-Chief of Annals of the Rheumatic Diseases (impact factor 14.299) from 2008 to 2017, President of the European League Against Rheumatism (EULAR) from 2005 to 2007, and acted as principal investigator of the Norwegian government-financed NOR-SWITCH study.
Professor Kvien was recognized as Master of the American College of Rheumatology in 2015, and is honorary member of the Norwegian, Finnish, and Czech rheumatological societies as well as the Norwegian Rheumatism Association. He also received the EULAR meritorious service award in 2017, the Carol Nachman medal in 2018 for his contributions to international rheumatology, and the Norwegian King recently appointed professor Kvien as Officer First Class of the Royal Order of St Olav.
Tore K Kvien has received fees for speaking and/or consulting from AbbVie, Biogen, Celgene, Celltrion, Egis, Evapharma, Ewopharma, Eli Lilly, Hikma, Hospira, MSD, Mylan, Novartis, Oktal, Orion Pharma, Pfizer.
An application has been made to the UEMS EACCME® for CME accreditation of this eLearning webcast.